Journal: Experimental Hematology & Oncology
Article Title: Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy
doi: 10.1186/s40164-025-00734-4
Figure Lengend Snippet: THM combined with clinical medications exhibited significant synergistic antitumor effect in colorectal cancer animal models. A HCT116 tumor-bearing athymic nude mice tumor inoculation [subcutaneous (s.c.)] and treatment plan. Nine days after tumor inoculation, mice were treated intraperitoneally with THM medium dose, Cetuximab, FOLFOX regimen (5-FU + Calcium levofolinate + Oxaliplatin), FOLFIRI regimen (5-FU + Calcium levofolinate + Irinotecan), THM + Cetuximab, THM + FOLFOX, and THM + FOLFIRI. The THM mid-dose group received 60 mg/kg every other day and the Cetuximab group received 1 mg/mouse daily. FOLFOX group received 5-FU (22.5 mg/kg) and Calcium levofolinate (33.75 mg/kg) on days 1 and 8 and Oxaliplatin (9.375 mg/kg) on days 2 and 9. FOLFIRI received 5-FU (22.5 mg/kg) and Calcium levofolinate (33.75 mg/kg) on days 1 and 8 and Iirinotecan (15 mg/kg) on days 2 and 9. B Photographs of the excised tumors from HCT116 xenograft bearing mice across different treatment groups were captured on day 20 ( n = 5). C-D The average tumor growth curves of all treatment groups. Data was shown as mean ± SD ( n = 5), and significance was determined using two-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001 and **** p < 0.0001). E Average body weight of HCT116 tumor-bearing mice during the treatment. Data was shown as mean ± SD ( n = 5). F-H Schematic diagrams for calculating the combination index (CI) after treatment with THM in combination with Cetuximab (F), the FOLFOX regimen (G), and the FOLFIRI regimen (H). Data was shown as mean ± SD ( n = 5), * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. I Immunohistochemical staining of PANoptosis indexes by subcutaneous tumor-bearing HCT116 colorectal cancer tumor tissue sections combined with clinical drugs (Cetuximab, FOLFOX and FOLFIRI regimens)
Article Snippet: 5-Fluorouracil (5-FU) (HY-9006), Irinotecan (HY-16562), Calcium levofolinate (HY-13667), Oxaliplatin (HY-17371), Necrostatin-1 (Nec-1) (HY-15760), Z-VAD-FMK (HY-16658B), Ferrostatin-1 (Fer-1) (HY-100579), Chloroquine (CQ) (HY-175889A) were acquired from MCE (Monmouth Junction, NJ, USA).
Techniques: Medications, Immunohistochemical staining, Staining
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
![THM combined with clinical medications exhibited significant synergistic antitumor effect in colorectal cancer animal models. A HCT116 tumor-bearing athymic nude mice tumor inoculation [subcutaneous (s.c.)] and treatment plan. Nine days after tumor inoculation, mice were treated intraperitoneally with THM medium dose, Cetuximab, FOLFOX regimen <t>(5-FU</t> + Calcium levofolinate + Oxaliplatin), FOLFIRI regimen (5-FU + Calcium levofolinate + Irinotecan), THM + Cetuximab, THM + FOLFOX, and THM + FOLFIRI. The THM mid-dose group received 60 mg/kg every other day and the Cetuximab group received 1 mg/mouse daily. FOLFOX group received 5-FU (22.5 mg/kg) and Calcium levofolinate (33.75 mg/kg) on days 1 and 8 and Oxaliplatin (9.375 mg/kg) on days 2 and 9. FOLFIRI received 5-FU (22.5 mg/kg) and Calcium levofolinate (33.75 mg/kg) on days 1 and 8 and Iirinotecan (15 mg/kg) on days 2 and 9. B Photographs of the excised tumors from HCT116 xenograft bearing mice across different treatment groups were captured on day 20 ( n = 5). C-D The average tumor growth curves of all treatment groups. Data was shown as mean ± SD ( n = 5), and significance was determined using two-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001 and **** p < 0.0001). E Average body weight of HCT116 tumor-bearing mice during the treatment. Data was shown as mean ± SD ( n = 5). F-H Schematic diagrams for calculating the combination index (CI) after treatment with THM in combination with Cetuximab (F), the FOLFOX regimen (G), and the FOLFIRI regimen (H). Data was shown as mean ± SD ( n = 5), * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. I Immunohistochemical staining of PANoptosis indexes by subcutaneous tumor-bearing HCT116 colorectal cancer tumor tissue sections combined with clinical drugs (Cetuximab, FOLFOX and FOLFIRI regimens)](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_1742/pmc12781742/pmc12781742__40164_2025_734_Fig9_HTML.jpg)